Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates

Non-alcoholic fatty liver disease (NAFLD), or metabolic (dysfunction)-associated fatty liver disease (MAFLD), is characterized by high global incidence and prevalence, a tight association with common metabolic comorbidities, and a substantial risk of progression and associated mortality. Despite the...

Descripción completa

Detalles Bibliográficos
Autores principales: Prikhodko, Veronika A., Bezborodkina, Natalia N., Okovityi, Sergey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869100/
https://www.ncbi.nlm.nih.gov/pubmed/35203484
http://dx.doi.org/10.3390/biomedicines10020274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869100/
https://www.ncbi.nlm.nih.gov/pubmed/35203484
http://dx.doi.org/10.3390/biomedicines10020274

Ejemplares similares